What do we know form The TORCH study about the treatment of chronic obstructive pulmonary disease_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

WANG Changzheng

Institute of Respiratory Disease, Xinqiao Hospital, Third Military Medical University. Chongqing , 400037 , China;

Corresponding?author：

Keywords：

慢性阻塞性肺疾病

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

慢性阻塞性肺疾病(COPD)的發病率和病死率在全球范圍內仍呈升高趨勢。吸煙是COPD最重要的發病危險因素。由于我國的吸煙人群高達3.5億，而且缺乏有效的控煙措施，所以可以預計在未來相當長的時間內，我國的COPD發病率和病死率仍會持續升高，繼續成為一個嚴重的公共衛生問題。近年來的多項臨床試驗證實噻托溴銨、沙美特羅／氟替卡松等藥物的應用可以改善COPD患者的癥狀及生活質量，甚至短期內改善一些肺功能指標。2006年新版的“慢性阻塞性肺疾病全球創議”(GOLD)將COPD定義為“可治療”的疾病，比過去GOLD 的定義增加了“樂觀”的成分。但是目前的這些藥物還不能改變COPD的自然病程，能否降低COPD的病死率也沒有明確的答案。因此，葛蘭素史克(GSK)公司發起了全球性的多中心臨床試驗——“邁向COPD患者健康的變革(TORCH)”研究[1]，研究的目的是驗證這樣的假設，即通過沙美特羅／氟替卡松3年的治療能降低所有原因導致的COPD死亡率，包括作者單位在內的44個國家444個醫學臨床研究中心參加了該研究。

Citation： WANG Changzheng. What do we know form The TORCH study about the treatment of chronic obstructive pulmonary disease. Chinese Journal of Respiratory and Critical Care Medicine, 2007, 6(4): 241-242. doi: Copy

1.	Vestbo J, TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J,2004,24:206-210.
2.	Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007,356: 775-789.
3.	La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med, 2007,356;2211-2212.
4.	Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.Chest,2006,129:15-26.
5.	Rabe KF. Treating COPD--the TORCH trial, P values, and the Dodo. Engl J Med,356,851-854.
6.	Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomized controlled trial. Eur Respir J,2007,29:906-913.

1. Vestbo J, TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J,2004,24:206-210.
2. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007,356: 775-789.
3. La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med, 2007,356;2211-2212.
4. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.Chest,2006,129:15-26.
5. Rabe KF. Treating COPD--the TORCH trial, P values, and the Dodo. Engl J Med,356,851-854.
6. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomized controlled trial. Eur Respir J,2007,29:906-913.

Chinese Journal of Respiratory and Critical Care Medicine

What do we know form The TORCH study about the treatment of chronic obstructive pulmonary disease

Abstract Full text Figures/Tables Video References Cited by

Format

Content